Evidence map›Paper›PMID 42230579›Full record

ArticleNature communications2026

Rational design of carbazole-based STING inhibitors for treating cGAS-STING pathway-driven inflammatory disorders.

Hui Li, Wei Zheng, Wenjing Bian, Mei Li, Zhidan Fan, Ziwen Feng, Xiaoyan Liu, Shiduo Zhang, Haohao Lu, Yinquan Huang and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hui Li *Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China.ORCID http://orcid.org/0009-0005-9191-9745
Wei Zheng *Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China.
Wenjing Bian *State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Mei LiState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Zhidan FanDepartment of Rheumatology and Immunology, Children's Hospital of Nanjing Medical University, Nanjing, China.
Ziwen FengJiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China.
Xiaoyan LiuState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Shiduo ZhangJiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China.
Haohao LuJiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China.
Yinquan HuangJiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China.
Jiaqing JiaJiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China.
Yifan ZhangJiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China.
Linlin LiJiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China.
Chunchen CheJiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China.
Haiguo YuDepartment of Rheumatology and Immunology, Children's Hospital of Nanjing Medical University, Nanjing, China. haiguo_yu@njmu.edu.cn.
Yibei XiaoState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China. yibei.xiao@cpu.edu.cn.ORCID http://orcid.org/0000-0003-4716-5526
Qidong YouJiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China. youqd@163.com.
Xiaoli XuJiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China. xuxiao_li@126.com.ORCID http://orcid.org/0000-0002-1126-2538

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82073766National Natural Science Foundation of China (National Science Foundation of China) 82273786National Natural Science Foundation of China (National Science Foundation of China) 82473848Outstanding Youth Foundation of Jiangsu Province of China BK20240199
6 · The paper itself

Abstract

Stimulator of Interferon Genes (STING) is a pivotal adaptor protein in the innate immune pathway, and its aberrant activation is closely associated with the pathogenesis of autoimmune diseases. Although it has emerged as an attractive therapeutic target for inflammatory disorders, current STING inhibitors still face challenges including off-target toxicity and limited understanding of binding mechanism. Herein, through a Target & Cell-based cascade screening and rational design, DDO-88109 with a carbazole scaffold is identified as a STING inhibitor, with IC

Indexed as

CarbazolesInflammationMembrane ProteinsNucleotidyltransferasesAnimalscGAS-STING Signaling PathwayCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseDrug DesignExodeoxyribonucleasesHumansMaleMicePhosphoproteinsSignal TransductionSTING ProteincarbazoleCarbazolescGAS protein, humanCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseExodeoxyribonucleasesMembrane ProteinsNucleotidyltransferasesPhosphoproteinsSTING1 protein, humanSTING Proteinthree prime repair exonuclease 1

Identifiers

PMID42230579
PMCPMC13392436

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.